Neurodegenerative disorders and nanoformulated drug development

Ari Nowacek, Lisa M. Kosloski, Howard E. Gendelman

Research output: Contribution to journalReview article

49 Scopus citations

Abstract

Degenerative and inflammatory diseases of the CNS include, but are not limited to, Alzheimer's and Parkinson's disease, amyotrophic lateral sclerosis, stroke, multiple sclerosis and HIV-1-associated neurocognitive disorders. These are common, debilitating and, unfortunately, hold few therapeutic options. In recent years, the application of nanotechnologies as commonly used or developing medicines has served to improve pharmacokinetics and drug delivery specifically to CNS-diseased areas. In addition, nanomedical advances are leading to therapies that target CNS pathobiology and as such, can interrupt disordered protein aggregation, deliver functional neuroprotective proteins and alter the oxidant state of affected neural tissues. This article focuses on the pathobiology of common neurodegenerative disorders with a view towards how nanomedicine may be used to improve the clinical course of neurodegenerative disorders.

Original languageEnglish (US)
Pages (from-to)541-555
Number of pages15
JournalNanomedicine
Volume4
Issue number5
DOIs
StatePublished - 2009

Keywords

  • Alzheimer's disease
  • Amyotrophic lateral sclerosis
  • Fullerene
  • Nanomedicine
  • Nanoparticles
  • Neurodegeneration
  • Neuroregeneration
  • Parkinson's disease
  • Stroke

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint Dive into the research topics of 'Neurodegenerative disorders and nanoformulated drug development'. Together they form a unique fingerprint.

  • Cite this